Stockwinners Market Radar for June 21, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
AZN | Hot Stocks19:56 EDT Ascentage Pharma enters collaboration to evaluate Bcl-2, BTK inhibitors combo - Ascentage Pharma has announced a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca. Under the terms of the collaboration, Ascentage will sponsor a clinical trial to study the combination of Ascentage Pharma's APG-2575, a selective Bcl-2 inhibitor, and Acerta's CALQUENCE, a Bruton's Tyrosine Kinase inhibitor, evaluating the efficacy and safety of this combination therapy in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. This global, multicenter, open-label Phase Ib/II dose-escalation and dose-expansion study is designed to evaluate the safety, tolerability, and anticancer activity of APG-2575 as a single agent or in combination with CALQUENCE in patients with r/r CLL/SLL. The study has already initiated in U.S. with the dosing of first patient, and planned to expand in Europe, and Australia.
|
TSN... | Hot Stocks19:54 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. China suspended poultry imports from a Tyson Foods (TSN) plant where hundreds of employees tested positive for COVID-19, Bloomberg's Marion Dakers and Michael Hirtzer reported. All products from the plant in Springdale, Arkansas, where Tyson is based, that are about to arrive in China or have arrived at the country's ports will be seized by customs, the authors noted, adding that the suspension is an about face from just a few days ago, when Chinese officials said food was unlikely to be responsible for a fresh virus outbreak in Beijing. Meanwhile, PepsiCo (PEP) said it shut a food plant in the Chinese capital after a case of the virus was confirmed earlier in the week, the publication added. 2. American Airlines (AAL) announced proposed underwritten public offerings of $750,000,000 of shares of its common stock and $750,000,000 aggregate principal amount of its convertible senior notes due 2025. The company intends to grant the underwriters of the offerings a 30-day option to purchase, in whole or in part, up to $112,500,000 of additional shares of Common Stock in the Common Stock Offering and a 30-day option to purchase, in whole or in part, up to $112,500,000 aggregate principal amount of additional Convertible Notes in the Convertible Notes Offering, in each case solely to cover over-allotments, if any. The company expects to use the net proceeds from the Common Stock Offering and the Convertible Notes Offering for general corporate purposes and to enhance the company's liquidity position. The company also announced it intends to enter into a new $500M Term Loan B Facility due 2024 concurrently with the closing of the offering of the Notes. The company expects to use a portion of the net proceeds from the offering of the Notes and borrowings under the Term Loan to refinance its delayed draw term loan facility which the company and the Guarantor entered into on March 18, 2020 and is scheduled to mature on March 17, 2021, with the remainder for general corporate purposes and to enhance the company's liquidity position. 3. The tech sector continues to drive the market higher, driven larger by the increased demand for cloud services, but there are still cheap tech stocks, if investors know where to look, Eric Savitz wrote in this week's edition of Barron's. Among cheap tech stocks are Western Digital (WDC), CACI International (CACI), Leidos Holdings (LDOS), Seagate Technology (STX), Amdocs (DOX), Ciena (CIEN), Accenture (ACN), MKS Instruments (MKSI), Intel (INTC), and F5 Networks (FFIV), the publication noted. On the flip side, some of the pricier tech names include DraftKings (DKNG), Datadog (DDOG), Zoom Video (ZM), Zscaler (ZS), Coupa Software (COUP), Okta (OKTA), Cloudflare (NET), Crowdstrike (CRWD), Atlassian (TEAM) and VEEVA Systems (VEEV). 4. PG&E (PCG) won final approval of its bankruptcy plan, clearing the way for the California utility giant to emerge from one of the darkest chapters of its history, Bloomberg's Mark Chediak reported. U.S. Bankruptcy Judge Dennis Montali issued an order Saturday confirming PG&E's Chapter 11 plan that will cover billions of dollars in damage claims stemming from catastrophic wildfires linked to the company's equipment, the author noted. 5. Brunswick (BC), Emerson Electric (EMR), Ametek (AME), Wabtec (WAB), and RBC Bearings (ROLL) saw positive mentions in this week's edition of Barron's.
|
AAL | Hot Stocks17:16 EDT American announces proposed offering of senior secured notes, new term loan - American Airlines announced a proposed private offering of $1.5B aggregate principal amount of secured senior notes due 2025. The Notes will be guaranteed on a senior unsecured basis by American Airlines Group. The company also announced it intends to enter into a new $500M Term Loan B Facility due 2024 concurrently with the closing of the offering of the Notes. The company expects to use a portion of the net proceeds from the offering of the Notes and borrowings under the Term Loan to refinance its delayed draw term loan facility which the company and the Guarantor entered into on March 18, 2020 and is scheduled to mature on March 17, 2021, with the remainder for general corporate purposes and to enhance the company's liquidity position. The final terms and amounts of the Notes and the Term Loan are subject to market and other conditions, and may be materially different than expectations. Neither the closing of the Notes offering nor the Term Loan is conditioned upon the closing of the other financing.
|
AAL | Hot Stocks17:14 EDT American announces proposed offerings of common stock, convertible senior notes - American Airlines announced proposed underwritten public offerings of $750,000,000 of shares of its common stock and $750,000,000 aggregate principal amount of its convertible senior notes due 2025. The company intends to grant the underwriters of the offerings a 30-day option to purchase, in whole or in part, up to $112,500,000 of additional shares of Common Stock in the Common Stock Offering and a 30-day option to purchase, in whole or in part, up to $112,500,000 aggregate principal amount of additional Convertible Notes in the Convertible Notes Offering, in each case solely to cover over-allotments, if any. The company expects to use the net proceeds from the Common Stock Offering and the Convertible Notes Offering for general corporate purposes and to enhance the company's liquidity position. The closing of neither the Common Stock Offering nor the Convertible Notes Offering is conditioned upon the closing of the other offering. Goldman Sachs, Citigroup, BofA Securities and JPMorgan are acting as the joint active book-runners and as representatives of the underwriters for the Common Stock Offering and the Convertible Notes Offering.
|
TSLA | Hot Stocks16:06 EDT Musk says Tesla to postpone annual shareholder meeting - Tesla's CEO Elon Musk said in a tweet that, "Yes, but we will have to postpone annual shareholder meeting, as still no large gatherings allowed by July 7th. Not sure of new date, but am guessing maybe a month or so later." Reference Link
|
SINT | Hot Stocks15:25 EDT Sintx Technologies announces SARS-COV-2 testing results - Sintx Technologies announced that in a controlled laboratory study, the SARS-CoV-2 virus was inactivated when exposed to Sintx's sintered silicon nitride powder. The company expects to share additional data soon, once the findings are published in a rapid-review forum. "The preliminary results are encouraging," said Sonny Bal, CEO of Sintx. "The antiviral data are consistent with the well-established anti-bacterial properties of Sintx's silicon nitride, and with previously reported effectiveness against several single-strand RNA viruses. Additional testing at independent, outside laboratories is in progress to corroborate the effectiveness of silicon nitride against SARS-CoV-2."
|
NBRV | Hot Stocks15:21 EDT Nabriva Therapeutics receives CRL from FDA on NDA for CONTEPO for injection - Nabriva Therapeutics announced that it received a Complete Response Letter from the U.S. Food and Drug Administration for the New Drug Application resubmission seeking marketing approval of CONTEPO for injection for the treatment of complicated urinary tract infections, including acute pyelonephritis. The company said that although Nabriva's European contract manufacturing partners were prepared for regulatory authority inspections, the CRL cites observations at the company's manufacturing partners that could not be resolved due to FDA's inability to conduct onsite inspections because of travel restrictions. In general, previously identified product quality and facility inspection related observations at its contract manufacturing partners are required to be satisfactorily resolved before the NDA may be approved. The FDA did not request any new clinical data and did not raise any other concerns with regard to the safety or efficacy of CONTEPO in the CRL. Nabriva plans to request a Type A meeting with the FDA to discuss appropriate next steps and the FDA's plans for completing foreign facility inspections. CONTEPO has been granted Qualified Infectious Disease Product and Fast Track designations by the FDA for the treatment of serious infections, including cUTI.
|